Dallas, TX (PRWEB) September 27, 2012
The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have been prescribed the blood thinner Pradaxa that the drug has been linked to severe internal bleeding which may outweigh its benefits. Also, a federal judge recently ruled that those injured may proceed with lawsuits.
Anyone affected by internal bleeding or the loss of a loved one from Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible.
Pradaxa is a popular anticoagulant drug prescribed to stop strokes and blood clots in patients with atrial fibrillation. Although only on the market since October, 2010, the drug has earned over $1 billion for manufacturer Boehringer Ingelheim and has been used in over 70 countries for the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.
On December 7, 2011, however, the FDA warned that it would launch an investigation into Pradaxa after receiving more injury or death reports than expected. According to USA Today on August 19, 2012, these totaled 3,781 side effect and 542 death reports among users in 2011, which led all other medications.
Now, a new study from the University of Pécs in Hungary released September 24, 2012 suggests the risks of Pradaxa may outweigh the benefits. Examining data from more than 31,000 patients over 10 years, researchers found that those taking drugs like Pradaxa after an acute coronary syndrome were three times as likely to have a bleeding event.
Due to the number of Pradaxa lawsuits expected from those injured, a central court was recently established in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. On September 5, 2012, the U.S. Panel on Multidistrict Litigation indicated that more than 100 Pradaxa lawsuits have been filed so far.
On July 25th, Judge David Herndon denied an attempt by Boehringer Ingelheim to dismiss the cases. Judge Herndon also set an initial hearing for October 3rd and indicated trials should start in 18 to 24 months.
Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Pradaxa Resource center only recommends lawyers who are already handling Pradaxa lawsuits.